Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Vedanta Biosciences (VE202 microbiome)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Bacterial product meant to treat inflammatory bowel diseases. The microbiome pharmaceutical candidate, VE202, is a mix of bacteria from the Clostridia subspecies that could be a treatment for Crohn's disease and ulcerative colitis. It will will help either replenish or rejuvenate a type of immune cell called regulatory T-cells, which help the body cool off inflammation.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Boston, MA
  • United States

Vedanta Biosciences (VE202 microbiome) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Vedanta Biosciences (VE202 microbiome)‘s full profile, request access.

Request full access to PitchBook

Vedanta Biosciences (VE202 microbiome) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Vedanta Biosciences (VE202 microbiome)‘s full profile, request access.

Request full access to PitchBook